diatrizoic acid has been researched along with Lymphatic Abnormalities in 2 studies
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.
Lymphatic Abnormalities: Congenital or acquired structural abnormalities of the lymphatic system (LYMPHOID TISSUE) including the lymph vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Picibanil (OK-432) was the primary agent used in most included studies." | 2.47 | Sclerotherapy for lymphatic malformations in children: a scoping review. ( Ali, A; Churchill, P; Flageole, H; Otal, D; Pemberton, J; Walton, JM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boardman, SJ | 1 |
| Cochrane, LA | 1 |
| Roebuck, D | 1 |
| Elliott, MJ | 1 |
| Hartley, BE | 1 |
| Churchill, P | 1 |
| Otal, D | 1 |
| Pemberton, J | 1 |
| Ali, A | 1 |
| Flageole, H | 1 |
| Walton, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
1 review available for diatrizoic acid and Lymphatic Abnormalities
| Article | Year |
|---|---|
Sclerotherapy for lymphatic malformations in children: a scoping review.
Topics: Adolescent; Adult; Bleomycin; Child; Child, Preschool; Diatrizoate; Drug Combinations; Evidence-Base | 2011 |
1 other study available for diatrizoic acid and Lymphatic Abnormalities
| Article | Year |
|---|---|
Multimodality treatment of pediatric lymphatic malformations of the head and neck using surgery and sclerotherapy.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Diatrizoate; | 2010 |